What is the
SPOT-MAS test?
Spot cancer signals early
SPOT-MAS is a non-invasive, multi-cancer early detection (MCED) test that detects tumor DNA (ctDNA) circulating in the blood. This test incorporates next-generation sequencing (NGS) and AI technologies to analyze the methylation profile and multiple features of ctDNA, enabling early detection for the 10 most common and aggressive cancers(*) from a single tube of blood.
Brochure:
Patient Guiding Handbook 11.40 MB 232 downloads
Spot early signals of 10 common and aggressive cancers using next generation of ctDNA...
Patient Guiding Handbook for Healthcare Professionals 19.45 MB 223 downloads
Spot early signals of common and aggressive cancers using next-generation of ctDNA...Find out more
What is ctDNA Multi–Cancer Early Detection?
What is ctDNA technology?
cfDNA (cell–free DNA): DNA fragments released passively from cells into bloodstream.
ctDNA (circulating tumor DNA): cell–free DNA released from tumor cells. Tumor cells release ctDNA actively with multiple features significantly different with cfDNA.
Benefits of ctDNA in Multi–cancer early detection
The practice of early detection for multiple cancers is an active search for a signal that many cancers share, thereby improving the probability of identifying cancer at an early stage.
ctDNA has been proved as an insightful signal in multi–cancer screening.(1)
- (1) Le Son Tran, et al. (2023) eLife 12:RP89083.
Why should we care?
Status of 10 common and AGGRESSIVE cancers
Mortality
No Data Found
10 cancer types
- Breast
- Lung
- Colorectum
- Stomach*
- Liver*
- Ovary*
- Pancreas*
- Esophagus*
- Uterus*
- Biliary tract*
*7/10
The WHO GLOBOCAN South–East Asia Report (2022) tracks the incidences of more than 3,000 new cases a day, spanning a total of 32 reported cancer types(1). Remarkably, 10 types of cancer, accounted for 56.2% of total new incidences and 59.9% of total mortality.
Only three among them (Breast, Lung, Colorectum) have established screening programs. The need for early–stage screening for more cancer types is crucial, given the rising incidence of cancers. Early detection can significantly improve survival rates and save lives.
- (1) WHO – GLOBOCAN 2022. South–Eastern Asia
The need for early detection
5–year survival rate percentage**
No Data Found
Main reasons for late detection:
- People with no obvious signs of cancer do not go for early cancer screening.
- Only few cancers types have recommended screening.
- Cancer symptoms mostly occur at late stage.
Late–stage diagnosis leads to(4):
- 5x higher mortality rate within 12 months.
- 50% higher chance of financial catastrophe.
- (2) Statistics adapted from the American Cancer Society’s (ACS) publication, Cancer Facts & Figures 2022 and Cancer Facts & Figures 2021; the ACS website; and the International Agency for Cancer Research website.
- (3) Sankaranarayanan, R., Ramadas, K., Qiao, Y., 2014. Managing the changing burden of cancer in Asia. BMC Med 12, 3.
- (4) ACTION (Asean CosTs in Oncology) STUDY, Singapore 2020.
What should we do to improve early detection?
Hereditary & Familial
25 -30% (1) attributed to all cancers
- Inherited from familial gene
- Mutations in a person genome from birth All cells in the body have these mutations
- May be passed to future generations
- Screen for hereditary cancer risks: common genes associated with specific types of cancer.
Occurred mutations
70% (1) attributed to all cancers
- Caused by age, environment & lifestyle habits
- Mutations acquired over time
- New mutations are present at the tumor only
- Will not be passed to future generations
- Screen for tumor presence at early stages by annual screening checkup or using ctDNA multi–cancer early detection test.
- (1) Garber J.E., Offit K. Hereditary Cancer Predisposition Syndromes. J. Clin. Oncol. 2005;23:276–292
